This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
As you will see, retail and mail prescription drug spending remain a consistently small share of the $4.5 And contrary to what you might read, drug spending growth was *not* driven by purportedly “skyrocketing” drug prices. Will drug pricing flat earthers (#DPFE) ever acknowledge the data? (Links below.) healthcare.
In this issue: An update on the retail pharmacy shakeout Arguing for high drug prices A leading researcher provides a 340B reality check Physicians don’t want pharmacists getting uppity Plus, Dave Grohl fights for your right to…have healthcare price transparency? (I Sorry, no Threads.) All rights reserved.
The biosimilar boom for provider-administered drugs continues to accelerate. Below, we share our estimates for wholesalers’ gross margins for brand-name, generic, and biosimilar drugs. We then explain the channel dynamics behind biosimilar and generic drugs’ profits. drug distribution. d/b/a Drug Channels Institute.
Vishali discusses the persistent challenges of duplicate discounts between the 340B Drug Pricing Program and the Medicaid Drug Rebate Program. To learn more, sign up now for priority access to Kalderos’ 2023 annual report: Mission Critical: Bringing Drug Discount Stakeholders Together so Patients Win.
Before you launch your July 4 festivities, Drug Channels offers some fireworks of our own: My $0.02 on the Humira price war—and the role of cost-plus pharmacy pricing Fresh evidence that formulary exclusions hurt patients Disturbing oncology drug benefit management Plus, an entertaining explanation of why the U.S.
As regular readers of Drug Channels know, U.S. distribution and dispensing channels for prescription drugs are undergoing significant evolution and consolidation as the changing economics of pharmaceuticals challenge conventional business models. drug wholesaling industry. All rights reserved.
Below, I explain why the IRA will encourage Part D plans to prefer high-list, high-rebate specialty drugs , even as the government and manufacturers will prefer a low-list-price version. As always, I encourage you to share your own thoughts with the Drug Channels community on social media. Actually, maybe not. P.S. Want to learn more?
Paula and I have some exciting news to share with you: Drug Channels Institute is joining the HMP Global family! Here’s the press release: HMP Global Expands Market Reach with Strategic Acquisition of Drug Channels Institute; Launches Market Intelligence Unit Paula and I will continue to lead DCI as part of HMP.
I am pleased to announce the inaugural Drug Channels Leadership Forum ! The Leadership Forum will be an executive gathering where drug channel leaders can network and discuss key issues and challenges facing the commercial healthcare system. And of course, I'll be there to moderate the entire event and lead the fireside chats.
This week, Im rerunning some popular posts while I prepare for todays Drug Channels Outlook 2025 live video webinar. (If As you will see below, CMS projects that outpatient prescription drugs dispensed by retail and mail pharmacies will remain a small share of total U.S. If you sign up before 12 p.m. ET, you can attend the live event.)
Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a jump of more than 35% compared with the previous year. Despite skyrocketing sales for anti-obesity GLP-1 drugs, many retail pharmacies are losing money on every prescription.
My recent Drug Channels Outlook 2024 webinar covered 12 key trends that will shape the commercial environment this year. The video excerpt below highlights my commentary on trend #2: the rapid growth of anti-obesity GLP-1 agonist drugs. Click here to sign up for The Drug Channels 2024 Video Webinar Series.
This week, I’m rerunning some popular posts while I prepare for today's live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. As you will see below, outpatient prescription drugs dispensed by retail and mail pharmacies are projected to remain a small share (8.4%) of total U.S. healthcare spending.
Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s latest live video webinar: Drug Channel Implications of the Inflation Reduction Act This event will be broadcast live on Friday, April 5, 2024, from 12:00 p.m. to 1:30 p.m. All rights reserved.
It's time for Drug Channels annual examination of U.S. brand-name drug pricing. For 2024, average brand-name drugs list prices grew by only 2.3%. Whats more, after adjusting for overall inflation, brand-name drug net prices dropped for an unprecedented seventh consecutive year. The bubble wont vanish overnight.
Clissold — The trio of CDER, CBER, and CDRH released a new draft guidance titled “ Use of Data Monitoring Committees in Clinical Trials ” that revises the 2006 guidance “Establishment and Operation of Clinical Trial Data Monitoring Committees” and, when final, will replace the 2006 guidance.
In this issue: A reality check on Express Scripts’ purported “cost-based” pharmacy network Mark Cuban explains how and why the PBM market will change Why two drug prices are better than one Pharmacists sing the retail pharmacy shakeout blues Plus, two Philly legends meet at a cardiology conference! d/b/a Drug Channels Institute.
It's time for a super-sized Halloween roundup of wicked Drug Channels ’ tales. The gross-to-net bubble for anti-obesity GLP-1 drugs walks among us. Mark Cuban Cost Plus Drug Company conjures a partnership with Alto Pharmacy. Plus, an epic meetup with two of my favorite drug channel experts.
This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. Thanks to the IRA, Part D Plans Will Prefer High-List, High-Rebate Drugs. It's time for Drug Channels ’ annual reality check on U.S. drug pricing. Details below.
Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for DCI’s new live video webinar: Drug Channels Outlook 2024 This event will be broadcast live on Friday, December 15, 2023 12:00 p.m. This event is part of The Drug Channels 2023 Video Webinar Series. Dr. Adam J.
Experts from across the industry will discuss how current and future drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Drug Channels readers will save 10% off when they use code 23DRCH10 and register prior to March 31, 2023.*
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content